UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39971 Landos Biopharma, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 81-5085535 (State or other jurisdict ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39971 Landos Biopharma, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 81-5085535 | | --- | --- | | (State o ...

Top-line Results from the NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Planned for Q4 2024 Exhibit 99.1 Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results Sufficient Cash to Fund Planned Operations into mid-2025 NEW YORK, March 21, 2024 –– Landos Biopharma, Inc. (NASDAQ: LABP) ("Landos" or "the Company"), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business upd ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39971 Landos Biopharma, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 81-5085535 (State or other juris ...

Financial Position - The company reported an accumulated deficit of $143.4 million as of June 30, 2023, and expects to incur substantial operating losses for at least the next several years [78]. - As of June 30, 2023, the company had cash, cash equivalents, and marketable securities totaling $44.7 million, which is expected to fund operations into the first half of 2025 [78]. - The company has not generated any revenue from product sales since its inception in 2017 [77]. - The company expects to incur significant expenses and operating losses for the foreseeable future, necessitating additional capital to fund operations [96]. - The company currently has no credit facility or committed sources of capital, which may limit its ability to finance operations [111]. - If additional capital is raised through equity or convertible debt securities, existing stockholders may experience significant dilution [111]. - The company may need to relinquish valuable rights to technologies or future revenue streams if it raises funds through third-party collaborations or licensing arrangements [111]. Research and Development - The company initiated the NEXUS trial, a Phase 2 proof-of-concept clinical trial for NX-13 in patients with moderate to severe ulcerative colitis, with top-line data expected by the fourth quarter of 2024 [73]. - NX-13 showed favorable safety and tolerability profiles in a Phase 1b trial, with clinical improvement signals observed as early as two weeks [73]. - The company has several preclinical product candidates, including LABP-73 for asthma and COPD, LABP-66 for multiple sclerosis and Alzheimer's disease, and LABP-69 for diabetic nephropathy and rheumatoid arthritis [74]. - Research and development expenses are anticipated to decrease in 2023 relative to 2022 due to the wind-down of previous clinical trial activities [81]. - Research and development expenses decreased to $2.5 million for the three months ended June 30, 2023, from $6.6 million in the same period of 2022, a reduction of $4.1 million attributed to decreased clinical activities [91]. - For the six months ended June 30, 2023, research and development expenses were $5.8 million, down from $17.4 million in 2022, reflecting a decrease of $11.6 million primarily due to reduced clinical activities [92]. - The company anticipates that expenses will increase in connection with ongoing research and development activities, particularly for clinical trials [105]. Operating Expenses - General and administrative expenses are expected to be slightly lower in 2023 compared to 2022, focusing resources on NX-13 development [88]. - General and administrative expenses were $2.0 million for the three months ended June 30, 2023, compared to $4.7 million in 2022, a decrease of $2.7 million mainly due to lower compensation and recruiting costs [94]. Cash Flow - Net cash used in operating activities for the six months ended June 30, 2023, was $13.3 million, compared to $34.5 million in the same period of 2022 [101]. - Net cash provided by financing activities during the six months ended June 30, 2023, was $13.6 million, primarily from the issuance of pre-funded warrants [104]. - The company believes its existing cash and marketable securities will be sufficient to fund operations into the first half of 2025 [107]. Revenue Outlook - Future commercial revenue is expected to be derived from products not anticipated to be commercially available for several years, if at all [111]. - The company has not generated any revenue from product sales and does not expect to do so for at least the next few years [105]. Accounting and Reporting - There were no material changes to critical accounting policies and estimates during the six months ended June 30, 2023 [113]. - The company is classified as a smaller reporting company and is not required to provide certain market risk disclosures [114].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Blacksburg, Virginia 24062 For the transition period from to Commission File Number: 001-39971 Landos Biopharma, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 81-5085535 (State or other jurisdiction of For the quarterly period ended March 31, 2023 incorporation or organization) P.O. Box 11239 OR ☐ TRANSITIO ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39971 Landos Biopharma, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 81-5085535 (State or other jurisdiction o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39971 Landos Biopharma, Inc. (Exact Name of Registrant as Specified in its Charter) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 81-5085535 (State or other juris ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39971 Landos Biopharma, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 81-5085535 (State or other jurisdicti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39971 Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submi ...